The 340B drug pricing program is a federal program that allows certain federally designated healthcare entities to purchase drugs at a discounted rate. 340B is overseen by the Office of Pharmacy Affairs located within the Health Resources and Services Administration (HRSA).

The 340B Program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. Manufacturers participating in Medicaid agree to provide outpatient drugs to covered entities at significantly reduced prices.

2024年5月8日 · Hospitals generated average spread profits as high as $13,617 per claim on cancer drugs paid for by the North Carolina State Health Plan for Teachers and State Employees. Treasurer Folwell is calling on state and federal lawmakers to reform the 340B Drug Pricing Program and to provide hospital price relief to state employees and taxpayers.

2017年4月6日 · Working Title of the funding program: 340B Drug Pricing Program. The purpose of this program is to grant support to qualifying agencies with securing low-cost medications for migrant and seasonal farmworker patients and their dependents.

This resource has been created by the 340B Prime Vendor Program to assist stakeholders by combining the most recently available 340B Medicaid state-specific data with publicly available federal data.

2019年9月3日 · The North Carolina Division of Health Benefits (DHB) would like to reiterate the 340B provider and claim submission requirements for both the outpatient pharmacy and Physician’s Drug Program (PDP). Providers are required to comply with all aspects of their respective clinical coverage policy to submit 340B claims for reimbursement.

The 340B Federal Drug Pricing Program expands access to affordable medications to low-income populations by supporting the operations of healthcare safety net providers. The program was created in 1992 with the enactment of Public Law 102-585 of the Veterans Health Care Act.

The 340B program should help vulnerable North Carolina patients. Instead, 340B hospitals, contract pharmacies and PBMs are using the program to earn massive profits at the expense of patients.

Here’s what the program looks like across the country and in North Carolina. 57% of all hospitals in the United States participate in the 340B program. Discounted 340B purchases reached nearly $54 billion in 2022 nationwide – 23% higher than in 2021. The number of contract pharmacies has grown nationwide by more than 8,000% since 2010.

billing guidance to providers when billing the 340B modifiers for drugs administered to dual-eligible beneficiaries. Important Instruction: The N.C. Division of Medical Assistance (DMA) recognizes that, beginning January 1, 2018, CMS will require providers to report the “JG” and “TB” modifiers on OPPS claims (bill type13X).